{"groups":[{"description":"Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15 administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.","id":"FG000","title":"All Enrolled Subjects"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Progressive disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}